{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-169686","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.890167+00:00","generated_at":"2026-06-25T03:33:49.535813+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PMV Pharma reports PC14586 Phase 1 data: 32% ORR at high doses, responses in 6 tumor types","bullets":["Overall response rate (ORR) 32% (8/25) in patients receiving daily dose ≥1150 mg; 24% (8/33) across all doses.","Partial responses observed in breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancers.","Maximum tolerated dose reached at 1500 mg twice daily; common AEs included nausea, vomiting, AST/ALT increases.","Phase 2 portion of PYNNACLE study expected to start early 2023; data provide proof of concept for p53 reactivation.","Data presented at ASCO 2022 by MD Anderson investigator; first-in-class small molecule targeting p53 Y220C mutation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-169686","json":"https://secwatch.observer/filing/0001193125-22-169686.json","markdown":"https://secwatch.observer/filing/0001193125-22-169686.md","text":"https://secwatch.observer/filing/0001193125-22-169686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522169686/0001193125-22-169686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522169686/d274688d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:33:49.535813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}